Literature DB >> 2556096

Glucose uptake by gliomas after treatment. A positron emission tomographic study.

J M Rozental1, R L Levine, R J Nickles, J A Dobkin.   

Abstract

Positron emission tomographic scanning with fludeoxyglucose F 18 (18F-fluorodeoxyglucose) was used to study acute changes in gliomas after chemotherapy. In six experimental subjects, scans were obtained before and at days 1, 7, and 30 after treatment. Five control patients with gliomas who did not undergo chemotherapy had two scans, 1 month apart. Ratios were calculated between peak tumor regional cerebral metabolic rate for glucose and contralateral white matter. The percent change in ratios relative to each patient's baseline scan was calculated. Ratios in three stable controls remained unchanged over the study interval; in two controls it increased 155% and 36% and both died of tumor progression. In experimental subjects, ratios increased 20% to 100% 24 hours after chemotherapy and then decreased until at 28 days they varied between 22% above and 35% below baseline. The increased fludeoxyglucose F 18 uptake at 24 hours could be from uncoupling oxidative phosphorylation or shunting glucose to ribose phosphates for salvage nucleoside synthesis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2556096     DOI: 10.1001/archneur.1989.00520480044018

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  18 in total

Review 1.  Positron emission tomography and the central nervous system.

Authors:  R O Robinson; C D Ferrie; M Capra; M N Maisey
Journal:  Arch Dis Child       Date:  1999-09       Impact factor: 3.791

Review 2.  Positron emission tomography (PET): expanding the horizons of oncology drug development.

Authors:  Lisa A Hammond; Louis Denis; Umber Salman; Paul Jerabek; Charles R Thomas; John G Kuhn
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

3.  Cancer treatment monitoring with fluorine-18 2-fluoro-2-deoxy-D-glucose and positron emission tomography: frustration or future.

Authors:  H Minn; R Paul
Journal:  Eur J Nucl Med       Date:  1992

Review 4.  Applications of positron emission tomography (PET) in neurology.

Authors:  Y F Tai; P Piccini
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-05       Impact factor: 10.154

5.  Changes in glucose uptake by malignant gliomas: preliminary study of prognostic significance.

Authors:  J M Rozental; R L Levine; R J Nickles
Journal:  J Neurooncol       Date:  1991-02       Impact factor: 4.130

Review 6.  Monitoring chemotherapy and radiotherapy of solid tumors.

Authors:  Wolfgang A Weber; Hinrich Wieder
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07       Impact factor: 9.236

Review 7.  Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.

Authors:  P Rigo; P Paulus; B J Kaschten; R Hustinx; T Bury; G Jerusalem; T Benoit; J Foidart-Willems
Journal:  Eur J Nucl Med       Date:  1996-12

8.  Evaluation of early response to SU101 target-based therapy in patients with recurrent supratentorial malignant gliomas using FDG PET and Gd-DTPA MRI.

Authors:  A G Vlassenko; B Thiessen; B J Beattie; M G Malkin; R G Blasberg
Journal:  J Neurooncol       Date:  2000       Impact factor: 4.130

Review 9.  Prediction of brain tumor therapy response by PET.

Authors:  R G Blasberg
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

10.  Acute changes in glucose uptake after treatment: the effects of carmustine (BCNU) on human glioblastoma multiforme.

Authors:  J M Rozental; J D Cohen; M P Mehta; R L Levine; J M Hanson; R J Nickles
Journal:  J Neurooncol       Date:  1993-01       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.